逐瘀泄毒汤治疗缺血性中风风痰瘀阻证的临床研究

发布时间：2018-04-17 20:36

本文选题：逐瘀泄毒汤 + 缺血性中风急性期　；参考：《辽宁中医药大学》2017年硕士论文

【摘要】：目的:探讨自拟逐瘀泄毒汤,治疗缺血性中风急性期风痰瘀阻证的临床疗效。材料与方法:将来自营口市中医院内一科的60例患者,采用随机抽签的方法随机分成试验组和对照组,两组各30例病人。对照组病人给以一般治疗、抗血小板聚集、中成药注射剂改善循环,神经保护等西医及对症治疗。试验组在对照组西医学常规治疗的基础上加用逐瘀泄毒汤,疗程为14天。在进行治疗之前和之后分别对两组患者施行神经功能缺损程度的NHISS评分,中医病类评分,日常生活能力的(ADL)Barthel评分,最终进行临床疗效的评价。结果:1.将两组患者的治疗前NHISS评分、Barthel评分、中医病类评分、性别、年龄、合并疾病等一般资料进行统计分析后,P0.05,说明不存在统计学差异,具有可比性。2.经过14天的治疗之后,收集两组患者的观察评价指标,比较NHISS评分、Barthel评分、中医病类评分,经过统计方法计算后P0.05,说明NHISS评分、Barthel评分,中医病类评分存在统计学意义,有可比性。3.两组患者临床疗效比较,试验组优于对照组。结论:1.本方不仅有利于促进神经功能的恢复,更能够提高预后生活质量指数,降低中医病类评分,提高临床疗效,且无明显不良反应。2.在常规西医治疗基础上,运用本方治疗缺血性中风急性期之风痰瘀阻证疗效好、安全性高。值得在临床上进行实践推广。
[Abstract]:Objective: to explore the clinical effect of Zhuyu Xiedu decoction (ZYXD) in treating wind and phlegm stasis syndrome in acute stage of ischemic apoplexy.Materials and methods: 60 patients from one department of Yingkou traditional Chinese Medicine Hospital were randomly divided into experimental group and control group with 30 patients in each group.Patients in the control group were given general treatment, antiplatelet aggregation, traditional Chinese patent medicine injection to improve circulation, nerve protection and other Western medicine and symptomatic treatment.The experimental group was treated with Zhuyu Xiedu decoction for 14 days on the basis of routine treatment of western medicine in the control group.Before and after the treatment, the patients in the two groups were evaluated with NHISS score, TCM disease score and ADL Barthel score.The result is 1: 1.The NHISS score, TCM disease score, sex, age, combined disease and other general data of the two groups were statistically analyzed before treatment (P 0.05), indicating that there was no statistical difference and was comparable. 2.After 14 days of treatment, the observation and evaluation indexes of the two groups were collected, and the NHISS score and the TCM disease score were compared. After the calculation of the statistical method, P0.05, it showed that the NHISS score and the TCM disease score had statistical significance.Comparable.The clinical efficacy of the two groups was better than that of the control group.Conclusion 1.This prescription not only can promote the recovery of nerve function, but also can improve the quality of life index of prognosis, reduce the score of TCM diseases, improve the clinical efficacy, and have no obvious adverse reactions. 2.On the basis of routine western medicine treatment, this prescription has good efficacy and high safety in treating wind and phlegm stasis syndrome in acute stage of ischemic apoplexy.It is worth popularizing in clinical practice.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R255.2

【参考文献】